Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance with preliminary data anticipated in…
- Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of…
Delivered first clinical data demonstrating target engagement and translation of PN chemistry’s impact in clinic; Adapting ongoing Phase 1b/2a FOCUS-C9…
Record Q2 Sales of $4.9 million, Q2 Net Earnings of $0.7 millionMISSISSAUGA, Ontario, May 12, 2022 (GLOBE NEWSWIRE) -- Microbix…
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative…
Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported in patients with severe COVID-19;…
- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to…
Transforms the company’s balance sheet with an equity financing to fund growth and a favourable resolution to amend the key…
Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to…
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)…